ethyl 2-[2-[2-(2-bromoethoxy)ethoxy]ethoxy]acetate | 308085-31-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 2-[2-[2-(2-bromoethoxy)ethoxy]ethoxy]acetate
• 英文别名: 2-[2-(2-bromoethoxy)ethoxy]ethoxy ethyl acetate；Br-PEG3-ethyl acetate
• CAS: 308085-31-6
• 化学式: C₁₀H₁₉BrO₅
• 分子量: 299.162
• InChiKey: NWUDANMVYLBFML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-[2-[2-(2-bromoethoxy)ethoxy]ethoxy]acetate 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 14-bromo-3-(carboxymethyl)-4-oxo-6,9,12-trioxa-3-azatetradecan-1-oic acid
  参考文献：
  名称：

  Multidentate ¹⁸F-Polypegylated Styrylpyridines As Imaging Agents for Aβ Plaques in Cerebral Amyloid Angiopathy (CAA)

  摘要：

  beta-Amyloid plaques (A beta plaques) in the brain are associated with cerebral amyloid angiopathy (CAA). Imaging agents that could target the A beta plaques in the living human brain would be potentially valuable as biomarkers in patients with CAA. A new series of F-18 styrylpyridine derivatives with high molecular weights for selectively targeting A beta plaques in the blood vessels of the brain but excluded from the brain parenchyma is reported. The styrylpyridine derivatives, 8a-c, display high binding affinities and specificity to A beta plaques (K-i = 2.87, 3.24, and 7.71 nM, respectively). In vitro autoradiography of [F-18]8a shows labeling of beta-amyloid plaques associated with blood vessel walls in human brain sections of subjects with CAA and also in the tissue of AD brain sections. The results suggest that [F-18]8a may be a useful PET imaging agent for selectively detecting A beta plaques associated with cerebral vessels in the living human brain.

  DOI：

  10.1021/jm2009106
• 作为产物：
  描述：

  三乙二醇 在 N-溴代丁二酰亚胺(NBS) 、 三氟化硼乙醚 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 ethyl 2-[2-[2-(2-bromoethoxy)ethoxy]ethoxy]acetate
  参考文献：
  名称：

  Multidentate ¹⁸F-Polypegylated Styrylpyridines As Imaging Agents for Aβ Plaques in Cerebral Amyloid Angiopathy (CAA)

  摘要：

  beta-Amyloid plaques (A beta plaques) in the brain are associated with cerebral amyloid angiopathy (CAA). Imaging agents that could target the A beta plaques in the living human brain would be potentially valuable as biomarkers in patients with CAA. A new series of F-18 styrylpyridine derivatives with high molecular weights for selectively targeting A beta plaques in the blood vessels of the brain but excluded from the brain parenchyma is reported. The styrylpyridine derivatives, 8a-c, display high binding affinities and specificity to A beta plaques (K-i = 2.87, 3.24, and 7.71 nM, respectively). In vitro autoradiography of [F-18]8a shows labeling of beta-amyloid plaques associated with blood vessel walls in human brain sections of subjects with CAA and also in the tissue of AD brain sections. The results suggest that [F-18]8a may be a useful PET imaging agent for selectively detecting A beta plaques associated with cerebral vessels in the living human brain.

  DOI：

  10.1021/jm2009106

文献信息

• Phenyldiazirine compounds and photoaffinity labeling reagent
  申请人：Hatanaka Yasumaru

  公开号：US06903223B1

  公开（公告）日：2005-06-07

  This invention offers a photoreactive labeling reagent consisting of a novel biotinylated phenyldiazirine compound; a photoaffinity labeling reagent consisting of a saccharide-linked biotinylated phenyldiazirine compound where a saccharide compound is introduced into the novel compound; and a novel diazirine compound for such a reagent. The invention covers a biotinylated phenyldiazirine compound of the following formula (II); a phenyldiazirine compound which is an intermediate for synthesizing the above; a saccharide-linked biotinylated phenyldiazirine compound derived from the compound of the formula (II) and a saccharide compound and a method for manufacturing the same; a photoreactive labeling reagent containing the compound of the formula (II); a photoaffinity labeling reagent containing the saccharide-linked biotinylated phenyldiazirine compound; and a method for labeling a saccharide receptor using the reagent.

  这项发明提供了一种光反应性标记试剂，包括一种新型生物素化苯基重氮化合物；一种光亲和标记试剂，包括一种糖链连接的生物素化苯基重氮化合物，其中将糖类化合物引入到该新型化合物中；以及用于该试剂的一种新型重氮化合物。该发明涵盖以下化学式（II）的生物素化苯基重氮化合物；一种用于合成上述化合物的中间体苯基重氮化合物；从化学式（II）的化合物和糖类化合物衍生的糖链连接的生物素化苯基重氮化合物及其制造方法；包含化学式（II）的化合物的光反应性标记试剂；包含糖链连接的生物素化苯基重氮化合物的光亲和标记试剂；以及使用该试剂标记糖类受体的方法。
• [EN] AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS<br/>[FR] AGENTS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE L'AMYLOÏDOSE
  申请人：UCL BUSINESS PLC

  公开号：WO2022058733A1

  公开（公告）日：2022-03-24

  The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agents and medicaments comprising such compounds. The compounds are based on a general structure A-L-B, wherein A is a group of formula (II) or of formula (III): or of formula (IV) or of formula (V) B is a group of formula (III), (IV), or (V), or a group of formula (VI) or a group of formula –R10Z, wherein: Z is selected from -CO2R', -CONR'R'', -SO2R' wherein R' and R'' are independently H or C1-C4 alkyl; and R10 is a C1-C4 alkylene or alkenylene group; and L represents a linker group which is a saturated or unsaturated chain of 5 to 13 carbon atoms.

  本发明涉及用于稳定甲状腺素前体蛋白的四聚体形式并保护其免受蛋白水解切割的化合物；用于预防和治疗甲状腺素前体蛋白淀粉样变性的化合物；以及包含此类化合物的药剂和药物。这些化合物基于一般结构A-L-B，其中A是公式(II)或公式(III)的基团：或公式(IV)或公式(V) B是公式(III)、(IV)或(V)的基团，或公式(VI)的基团或公式-R10Z的基团，其中：Z从-CO2R'、-CONR'R''、-SO2R'中选择，其中R'和R''分别是H或C1-C4烷基；而R10是C1-C4烷基或烯基基团；L代表一个由5到13个碳原子组成的饱和或不饱和链的连接基团。
• US6903223B1
  申请人：——

  公开号：US6903223B1

  公开（公告）日：2005-06-07
• Multidentate ¹⁸F-Polypegylated Styrylpyridines As Imaging Agents for Aβ Plaques in Cerebral Amyloid Angiopathy (CAA)
  作者：Zhihao Zha、Seok Rye Choi、Karl Ploessl、Brian P. Lieberman、Wenchao Qu、Franz Hefti、Mark Mintun、Daniel Skovronsky、Hank F. Kung

  DOI：10.1021/jm2009106

  日期：2011.12.8

  beta-Amyloid plaques (A beta plaques) in the brain are associated with cerebral amyloid angiopathy (CAA). Imaging agents that could target the A beta plaques in the living human brain would be potentially valuable as biomarkers in patients with CAA. A new series of F-18 styrylpyridine derivatives with high molecular weights for selectively targeting A beta plaques in the blood vessels of the brain but excluded from the brain parenchyma is reported. The styrylpyridine derivatives, 8a-c, display high binding affinities and specificity to A beta plaques (K-i = 2.87, 3.24, and 7.71 nM, respectively). In vitro autoradiography of [F-18]8a shows labeling of beta-amyloid plaques associated with blood vessel walls in human brain sections of subjects with CAA and also in the tissue of AD brain sections. The results suggest that [F-18]8a may be a useful PET imaging agent for selectively detecting A beta plaques associated with cerebral vessels in the living human brain.